[What is ataxia? - Towards developing a new scale for ataxia]

Area of Science:

• Neuroscience
• Clinical Trials
• Biomarkers

Context:

• Ataxias are a group of neurological disorders characterized by a lack of voluntary muscle coordination.
• Despite significant progress in understanding the molecular mechanisms of ataxias, effective treatments remain elusive.
• Current clinical trial scales for evaluating ataxia therapies lack the sensitivity and stability required for efficient drug development.

Purpose:

• To highlight the limitations of existing ataxia scales in clinical trials.
• To emphasize the need for developing a new, continuous scale for ataxia evaluation.
• To explore recent advances in understanding cerebellar function for potential therapeutic targets.

Summary:

• Existing ataxia scales are insensitive and unstable, requiring large participant numbers and long trial durations.
• Categorical scales commonly used for ataxia assessment are less sensitive than continuous scales.
• The development of a novel, continuous scale is crucial for successful ataxia clinical trials and therapeutic advancement.

Impact:

• A new continuous scale will enhance the sensitivity and stability of clinical trial outcome measures for ataxias.
• Improved outcome measures will facilitate the development of effective drugs that prevent disease progression or improve symptoms.
• This advancement is expected to accelerate the clinical trial process, leading to faster availability of novel ataxia therapies.